The DOI matches its Crossref record.
Monoamine oxidase inhibitor-responsive depression
Abstract
Double-blind, placebo-controlled trials have documented the efficacy of some monoamine oxidase (MAO) inhibitors in treating certain depressed patients. This preliminary report of a 6-week, double-blind, placebo-controlled study of the MAO inhibitor isocarboxazid (Marplan) examines the time course of platelet MAO inhibition and treatment response, and describes symptoms that distinguish markedly improved from slightly improved responders. Thirty male outpatients, ages 28-64, randomly divided into placebo (n = 15) and active medication (n = 15) groups, were followed weekly. Medication was started at 20 mg daily and increased to achieve 90% platelet MAO inhibition. Data were analyzed for 24 patients who completed at least 3 weeks of the study. A clinician's global change rating at the study's conclusion showed that 12 of 13 patients (92%) in the active medication group improved, while 3 of 11 (27%) patients in the placebo group improved. Significant symptomatic improvement occurred in the active treatment group by week 3. Trends suggest that anxiety improved first (week 2), followed by depression (week 3), and finally cognitive outlook (week 6). Only minimal difficulties were observed with orthostatic hypotension, hypertensive crises, or other side effects. At baseline, the only significant difference between the markedly improved and slightly improved groups was greater psychomotor retardation in the markedly improved group. Trends suggest that the markedly improved group showe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Isocarboxazid (20mg) did not differ from placebo on HAMD sleep scores, but treatment responders tended to sleep better overall with isocarboxazid than with placebo.
“(Giller et al., 1982) demonstrated that isocarboxazid (20mg) did not differ from placebo on HAMD sleep scores, but treatment responders tended to sleep better overall with isocarboxazid than with placebo.”
From Antidepressants and their effect on sleep (2005) · cites this paper as Giller et al., 1982
Subjective reports of sleep were favourable with tranylcypromine and isocarboxazid.
“Nevertheless, subjective reports of sleep were favourable with tranylcypromine (Nolen et al., 1993) and isocarboxazid (Giller et al., 1982).”
From Antidepressants and their effect on sleep (2005) · cites this paper as Giller et al., 1982
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 15
- Bartonicek, 1970, Special application of flourescence histochemistry: Studies of eight monoamine oxidase inhibitors in brain neurons, Pharmacology, 4, 16, 10.1159/000136118 · DOI
- Cadoret, 1980, Somatic complaints: Harbinger of depression in primary care, Journal of Affective Disorders, 2, 61, 10.1016/0165-0327(80)90022-1 · DOI
- DiMascio, 1979, Differential symptom reduction by drugs and psychotherapy in acute depression, Archives of General Psychiatry, 36, 1450, 10.1001/archpsyc.1979.01780130068008 · DOI
- Giller, 1980, Platelet MAO and amitriptyline treatment, Psychiatry Research, 2, 259, 10.1016/0165-1781(80)90018-9 · DOI
- Giller, 1980, MAO inhibitors and platelet MAO inhibition, Communications in Psychopharmacology, 4, 79
- Glassman, 1979, Clinical characteristics of imipramine-induced orthostatic hypotension, Lancet, I, 468, 10.1016/S0140-6736(79)90824-9 · DOI
- Heise, 1960, Behavioral determinatio of time and dose parameters of monoamine oxidase inhibitors, Journal of Pharmacology and Experimental Therapeutics, 129, 155
- Pollit, 1971, Anxiety state or masked depression? A study based on the action of monoamine oxidase inhibitors, British Journal of Psychiatry, 119, 143, 10.1192/bjp.119.549.143 · DOI
- Quitkin, 1979, Monoamine oxidase inhibitors, Archives of General Psychiatry, 36, 749, 10.1001/archpsyc.1979.01780070027003 · DOI
- Ravaris, 1980, Phenelzine and amitriptyline in the treatment of depression, Archives of General Psychiatry, 37, 1075, 10.1001/archpsyc.1980.01780220113013 · DOI
- Robinson, 1978, Clinical pharmacology of phenelzine, Archives of General Psychiatry, 35, 629, 10.1001/archpsyc.1978.01770290111010 · DOI
- Robinson, 1973, The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states, Archives of General Psychiatry, 29, 407, 10.1001/archpsyc.1973.04200030093015 · DOI
- Tyrer, 1976, Towards rational therapy with monoamine oxidase inhibitors, British Journal of Psychiatry, 128, 354, 10.1192/bjp.128.4.354 · DOI
- West, 1959, Effects of iproniazid in depressive syndromes, British Medical Journal, 1, 1491, 10.1136/bmj.1.5136.1491 · DOI
- Zbinden, 1960, Clinical and pharmacological considerations on mode of action of monoamine oxidase inhibitors, Diseases of the Nervous System, 21, 89
Cited by
Sorted by citations
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323
Metadata
- Authors
- Giller, E., Bialos, D., Riddle, M., Sholomskas, A., & Harkness, L.
- Affiliations
- United States Department of Veterans Affairs (US)
- Yale University (US)
- Corresponding author
- Giller, Earl
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 1982-02
- Volume
- 6
- Issue
- 1
- Pages
- 41-48
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W2024636395
- Cited by
- 28
- References
- 0
- Citations by year
- 2025: 1
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- monoamine oxidase inhibitors, isocarboxazid, depression, antidepressant efficacy, treatment response, anxiety, psychomotor retardation, orthostatic hypotension, hypertensive crisis, adverse effects
- MeSH terms
- Adult, Clinical Trials as Topic, Depressive Disorder, Double-Blind Method, Humans, Isocarboxazid, Male, Middle Aged, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
